Skip to content
    Clinical Trials

    Fractionated Gamma Knife yields durable local control in non-glial brain tumor cohort

    Udovicich et alJournal of Neuro-Oncology

    Fractionated Gamma Knife yields durable local control in non-glial brain tumor cohort
    This study evaluated the efficacy and safety profile of salvage conventionally fractionated Gamma Knife stereotactic radiotherapy (SFGK) for patients with recurrent, previously irradiated primary non-glial intracranial tumors. Between 2019 and 2024, 26 consecutive patients presenting with 44 progressive tumors were treated. The cohort consisted predominantly of meningiomas (77%, n = 34), of which 28 were categorized as WHO Grade 2. The median duration between the initial radiation course and salvage reirradiation was 50.4 months (interquartile range [IQR], 19.7–86.8 months).
    The standard SFGK regimen was 50.4 Gy delivered in 28 fractions, utilized in 84% of treated tumors (n = 37). For patients with a single prior course of radiation therapy, the median cumulative prescription equivalent dose in 2-Gy fractions (EQD2) was 102.7 Gy (IQR, 99.6–114.6 Gy), and the median normal brain cumulative EQD2 reached 99.2 Gy (IQR, 97.9–117.5 Gy). Over a median follow-up of 18.1 months (IQR, 10.5–28.2 months), durable disease control was demonstrated. The primary endpoint of overall local progression-free survival (LPFS) was 91.0% (95% CI, 73.6–97.2%) at 12 months and 75.1% (95% CI, 51.0–88.6%) at 24 months. Corresponding overall survival (OS) rates were 96.2% (95% CI, 75.7–99.4%) and 83.2% (95% CI, 54.8–94.6%). Among patients with meningiomas, 12- and 24-month LPFS rates were 90.6% (95% CI, 65.7–97.7%) and 74.1% (95% CI, 42.7–90.0%), respectively.
    Safety evaluations revealed an acceptable therapeutic window despite significant cumulative intracranial doses. Severe toxicities were limited: Grade 3 radiation necrosis developed in two patients (6.9%), and one patient experienced Grade 3 progressive intracranial hemorrhage (3.4%). No treatment-related Grade 4 toxicities or deaths (Grade 5) were reported. These findings support SFGK reirradiation as a feasible, well-tolerated salvage approach capable of providing durable tumor control in recurrent non-glial brain tumors.

    Key Takeaways

    • Salvage conventionally fractionated Gamma Knife stereotactic radiotherapy (SFGK) achieved 12- and 24-month local progression-free survival rates of 91.0% (95% CI 73.6–97.2%) and 75.1% (95% CI 51.0–88.6%), with overall survival rates of 96.2% and 83.2%, respectively.
    • In the subgroup of recurrent meningiomas (predominantly WHO Grade 2), 12- and 24-month local progression-free survival reached 90.6% (95% CI 65.7–97.7%) and 74.1% (95% CI 42.7–90.0%).
    • Severe toxicity was limited to Grade 3 radionecrosis in 6.9% of patients and Grade 3 progressive intracranial hemorrhage in 3.4%, with no Grade 4 or 5 adverse events observed despite a median cumulative prescription EQD2 of 102.7 Gy.
    Read the original sourceJournal of Neuro-Oncology